CYAD-211, using a miRNA-based shRNA approach to silence the CD3ζ component of the TCR while co-expressing an anti-BCMA CAR, was tested in the IMMUNICY-1 Phase I trial for relapsed/refractory multiple myeloma. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.